Tag: Cancer: Lung
Adding Selumetinib to Docetaxel Doesn’t Up PFS in NSCLC
No improvement in progression-free survival for previously treated advanced KRAS-mutant NSCLC
Blood-Based Genome Testing Feasible for Rapid Mutation Assay
Mutation results available within 72 hours for 94 percent of non-small-cell lung CA samples evaluated
Chromosome Instability Test Prognostic in NSCLC
Chromosome instability associated with higher risk of relapse, death within 2 years
AACR: Five-Year Survival 16 Percent With Nivolumab in NSCLC
Of the 16 patients who survived at least five years, nine were male, 12 were current smokers at baseline
Raised CTCs Precede Recurrence in Locally-Advanced NSCLC
Fifteen of 20 patients with recurrence had increase in circulating tumor cell counts post chemoradiation
Counseling Visit Helps Patients Decide About Lung CA Screening
Improves patient knowledge of eligibility criteria, benefits, harms of screening with low-dose CT
Pravastatin Does Not Improve Survival in Small-Cell Lung Cancer
Median overall survival of 10.6 versus 10.7 months for pravastatin versus placebo added to chemo
Biomarker in Nasal Passages May ID Lung Cancer in Smokers
Simple technique is based on cancer DNA and seems accurate for use after chest CT scan, researchers say
Lung Cancer Screening Rates Low Among Current, Former Smokers
Such testing could cut mortality rate by 20 percent, American Cancer Society says
Many VHA Patients Eligible for Lung Cancer Screening
Second study shows increase in lung cancer screening from 1.3 to 2.1 percent from 2010 to 2015
